Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIofina Regulatory News (IOF)

Share Price Information for Iofina (IOF)

Share Price is delayed by 15 minutes
Get Live Data
45.00    2.50 (5.88%)
Bid:
44.00
Ask:
46.00
Spread: 2.00 (4.545%)
Market Cap: £86.34m
IOF Live PriceLast checked at - London Stock Exchange

Intraday Iofina Share Chart

Market Update

25 Feb 2020 12:00

RNS Number : 0738E
Iofina PLC
25 February 2020
 

 

25 February 2020

 

Iofina plc

("Iofina", the "Group", or the "Company")

(LSE AIM: IOF)

 

 Market Update

 

IofinaEX update

 

Construction of IO#8 on budget and on track

 

Iodine prices continue to rise

 

Iofina plc, specialists in the exploration and production of iodine and manufacturers of specialty chemical products, is pleased to provide an update to the market regarding its ongoing operations and new projects.

 

IofinaEX

IofinaEX, continues to make progress in developing its technology to isolate specialty chemicals from hemp. Active trials continue at our facility in Kentucky whose Hemp Processor/Handler license was recently renewed.

 

As part of the initial work to set up IofinaEX, the Group has been evaluating business opportunities in Belize and elsewhere. Following this early evaluation process, which has been carried out at minimal expense, the Directors have concluded that the best strategy to grow IofinaEX would be to initially focus on the excellent CBD opportunities it has in the USA, a highly regulated market which Iofina currently operates in and understands well. This will also allow Iofina to continue the strong progress being made within its core iodine and specialty chemical businesses in the USA.

 

IofinaEX continues to develop its strategy in the CBD/Hemp space and will update the market as the business plan evolves in this dynamic market. Fully developing and communicating this business plan has taken longer than anticipated as the CBD/hemp global market is changing rapidly. Furthermore, despite now focusing on USA opportunities, IofinaEX will still continue to evaluate prospects outside of the USA as they present themselves.

 

IO#8

The construction of IO#8 continues to progress well, on budget and on track to be brought online likely in April 2020. Installation of steel, tanks, electrical and plumbing has progressed well, with other key components expected to be fitted within the next few weeks. Once in production, IO#8 will contribute fully to the Group's H2 2020 production output adding to Iofina's four operating iodine plants in Oklahoma.

 

http://www.rns-pdf.londonstockexchange.com/rns/0738E_1-2020-2-25.pdf

 

 

Figure 1. Construction of IO#8 in western Oklahoma

Iodine market

Iodine prices rose over 20% in 2019 and continue to rise in early 2020. The spot price now sits in the mid $30's per kilogram and is rising towards the upper $30's as a result of the continuing demand for iodine and a tightness in supply. The Directors believe that iodine prices will continue to increase in 2020. To date we have not seen any impact from the COVID-19 virus outbreak to the overall iodine market and specifically to the Group's sales or supply chain.

 

 

Commenting, President and CEO of Iofina, Dr. Tom Becker, stated: "As we approach the completion of IO#8 we are excited to see the plant come online in the months ahead, and to begin contributing to the Group's 2020 iodine output.

 

"Iodine markets have remained strong, after a solid 2019, and the Directors are confident that prices will continue to favour the Group as it progresses through 2020.

 

"Having now refocused efforts for IofinaEX, along with the Group's core iodine business lines to concentrate on opportunities in the USA, the Directors are confident that Group resources will be properly utilised, that risk has been minimised and Iofina will maximise the value delivered for shareholders."

 

Enquiries:

 

Dr. Tom Becker

CEO & President

Iofina plc

Tel: +44 (0)20 3006 3135

 

Christopher Raggett/Giles Rolls/Matthew Radley (corporate finance)

Camille Gochez (ECM)

finnCap Ltd

Tel: +44 (0)20 7220 0500

 

Media Contact:

Charles Goodwin/Joe Burgess

Yellow Jersey PR Limited

Tel: +44 (0)20 3004 9512

About Iofina:

Iofina plc (AIM: IOF) is a vertically integrated Company that specialises in the production of iodine and the manufacturing of specialty chemical products. As the second largest producer of iodine in North America, it comprises three USA entities; Iofina Resources, Iofina Chemical and IofinaEX.

 

LEI: 213800QDMFYVRJYYTQ84

ISIN: GB00B2QL5C79

 

Iofina Resources

Iofina Resources develops, builds, owns and operates iodine extraction plants using Iofina's WET® IOsorb® technology. Iofina currently operates four producing IOsorb® plants in Oklahoma, is building a fifth site, and is consistently using technology and innovation to improve and expand its operations.

 

Iofina Chemical

Iofina Chemical has manufactured high quality halogen speciality chemicals derived from raw iodine, as well as non-iodine based products for over 35 years.

 

IofinaEX

Iofina's newest subsidiary, IofinaEX, is fully licensed to process hemp in the state of Kentucky and is exploring the isolation of specialty chemical products from hemp, a rapidly expanding market.

 

www.iofina.com

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
UPDSEWFFIESSELE
Date   Source Headline
9th May 20237:00 amRNSNotice of AGM
4th May 20237:00 amRNSInvestor Presentation
28th Apr 20234:45 pmRNSHolding(s) in Company
28th Apr 20237:00 amRNSGrant of Share Options
25th Apr 20237:00 amRNS2022 FULL YEAR RESULTS
12th Apr 20237:00 amRNSProduction Update
20th Feb 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Update
9th Jan 20237:00 amRNSMarket Update
28th Dec 20222:34 pmRNSHolding(s) in Company
14th Dec 20227:00 amRNSIofina Chemical Awarded ISO Certification
21st Nov 20227:00 amRNSChange of Adviser
28th Oct 20227:00 amRNSFinalised Terms for IO9 & Q3 Production Update
26th Sep 202211:06 amRNSSecond Price Monitoring Extn
26th Sep 202211:00 amRNSPrice Monitoring Extension
26th Sep 20227:00 amRNSInterim Results
8th Jul 20227:00 amRNSAdditional Loan Facilities and H1 Update
5th Jul 20228:54 amRNSHolding(s) in Company
22nd Jun 20222:30 pmRNSResult of AGM
20th Jun 20227:00 amRNSAppointment of Chrystal Capital Partners LLP
27th May 20227:00 amRNSNotice of AGM
26th May 20224:15 pmRNSHolding(s) in Company
26th May 20222:15 pmRNSHolding(s) in Company
24th May 20226:15 pmRNSHolding(s) in Company
20th May 20227:10 amRNSInvestor Presentation
18th May 20227:00 amRNSHolding(s) in Company
9th May 20227:00 amRNSFinal Results
5th May 20227:00 amRNSHolding(s) in Company
28th Apr 20228:38 amRNSHolding(s) in Company
19th Apr 20227:00 amRNSQ1 2022 and IO#9 Update
8th Apr 20221:07 pmRNSHolding(s) in Company
17th Mar 20227:00 amRNSDirector/PDMR Shareholding
16th Mar 20227:00 amRNSHolding(s) in Company
14th Mar 20227:00 amRNSDirector/PDMR Shareholding
11th Mar 20227:00 amRNSDirector/PDMR Shareholding
10th Mar 20227:00 amRNSDirector/PDMR Shareholding
9th Mar 20227:00 amRNSGrant of Share Options
8th Mar 20228:51 amRNSHolding(s) in Company
17th Jan 20229:00 amRNSPrice Monitoring Extension
17th Jan 20227:00 amRNSQ4 2021 Update
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
10th Jan 20227:00 amRNSHolding(s) in Company
29th Dec 20217:00 amRNSBusiness Update
20th Oct 202112:44 pmRNSHolding(s) in Company
15th Oct 20217:00 amRNSQ3 2021 Update
12th Oct 20218:47 amRNSHolding(s) in Company
24th Sep 20217:00 amRNSInterim Results
23rd Sep 20214:40 pmRNSSecond Price Monitoring Extn
23rd Sep 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.